. 2021 Mar 7;8(3):2058–2069. doi: 10.1002/ehf2.13285

Table 3.

Multivariable predictors of cardiovascular mortality and HHF

Variables	Total study population (n = 415)			Patients with follow‐up echocardiography within 6 months (n = 289) ^b			Patients with follow‐up echocardiography within 12 months (n = 371) ^c
Variables	Adjusted HR	95% CI	P‐value	Adjusted HR	95% CI	P‐value	Adjusted HR	95% CI	P‐value
Age >70 years	1.810	1.080–3.031	0.024	2.460	1.363–4.440	0.003	‐	‐	‐
Diabetes mellitus	1.725	1.058–2.813	0.029	2.460	1.363–4.440	0.003	2.234	1.295–3.854	0.004
LV hypertrophy ^a	2.093	0.928–4.721	0.075	6.065	1.845–19.938	0.003	2.815	1.251–6.335	0.012
LV‐EDV index ≥91 mL/m² (median)	1.754	1.031–2.983	0.038
PASP >50 mmHg	2.657	1.603–4.405	<0.001	2.115	1.120–3.992	0.021	1.815	1.009–3.267	0.047
Use of BB	0.370	0.165–0.833	0.016	‐	‐	‐	‐	‐	‐
Dosage of sacubitril/valsartan at last follow‐up ≥200 mg/day	0.407	0.243–0.680	0.001	0.494	0.260–0.938	0.031	0.362	0.207–0.633	<0.001
Reverse remodelling within 6 months ^b	‐	‐	‐	0.409	0.217–0.769	0.006	‐	‐	‐
Reverse remodelling within 12 months ^c	‐	‐	‐	‐	‐	‐	0.313	0.181–0.542	<0.001

Univariable factors with P values <0.200 were entered into the multivariable Cox proportional hazard regression analysis, using the stepwise backward elimination method. Variables with a significant association with the composite endpoint of cardiovascular death and HHF are shown.

^{^a}

LV hypertrophy was defined according to the American Society of Echocardiography's guidelines ⁷ : LV‐MI > 95 g/m² in women and >115 g/m² in men.

^{^b}

LV reverse remodelling within 6 months of sacubitril/valsartan treatment initiation was determined in 289 patients for whom follow‐up echocardiograms within 6 months were available. Multivariable Cox proportional hazard regression analysis was performed with these 289 patients.

^{^c}

LV reverse remodelling within 12 months of sacubitril/valsartan treatment initiation was determined in 371 patients for whom follow‐up echocardiograms within 6 months were available. Multivariable Cox proportional hazard regression analysis was performed with these 371 patients.

BB, beta‐blockers; CI, confidence interval; HHF, hospitalization for heart failure; HR, hazards ratio; LV, left ventricular; MI, mass index; PASP, pulmonary artery systolic pressure.